Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Chris Dupont und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, Ohio, USA. Hauptthemen laut MEDLINE: Action Potentials, Paralysis, Hyperkalemic Periodic, Myotonia, Dantrolene. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
Hyperkalemic periodic paralysis (hyperKPP) is characterized by attacks of transient weakness. A subset of hyperKPP patients suffers from transient involuntary contraction of muscle (myotonia). The goal of this study was to determine mechanisms causing myotonia in hyperKPP.
Methods
Intracellular electrophysiology, single‐fiber Ca 2+ imaging, and whole muscle contractility studies were performed in a mouse model of hyperKPP.
Results
Myotonia in hyperkPP was caused by both involuntary myogenic action potentials (AP myotonia) lasting less than 5 min and action potential‐independent myotonia (non‐AP myotonia) lasting over 1 h. Non‐AP myotonia was caused by prolonged subthreshold depolarization and elevated intracellular Ca 2+ in the absence of action potentials. Treatment with dantrolene effectively mitigated non‐AP myotonia, suggesting that the source of Ca 2+ was the sarcoplasmic reticulum. Although non‐AP myotonia occurred in the absence of action potentials, Na + channel blockers were effective as therapy.
Discussion
We propose myotonia in hyperKPP occurs via two mechanisms: (1) suprathreshold depolarization triggering action potentials that are detectable with EMG and (2) sustained subthreshold depolarization resulting in Na + overload and Ca 2+ leak from the sarcoplasmic reticulum. Notably, clinical diagnostics such as EMG cannot detect the second mechanism as it occurs in the absence of action potentials. Currently, only a minority of patients with hyperKPP are treated with Na + channel blockers and none are treated with dantrolene. Our data suggest hyperKPP patients, as well as patients with a number of other neuromuscular disorders, may benefit from trials of these therapies, even if they do not have myotonia detectable clinically or by EMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, Ohio, USA.
- Department of Clinical Neurosciences, Wright State University, Dayton, Ohio, USA.
- Department of Biological Sciences, Wright State University, Dayton, Ohio, USA.
ORCID-Profile: Mark M Rich
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Dupont, C., Deardorff, A., Nawaz, M., Voss, A. A., & Rich, M. M. (2025). Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70134
Vancouver
Dupont C, Deardorff A, Nawaz M, Voss AA, Rich MM. Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70134
BibTeX
@article{Dupont2025,
author = {Dupont, Chris and Deardorff, Adam and Nawaz, Murad and Voss, Andrew A and Rich, Mark M},
title = {Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70134}
}
EUVIMED